ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q3 2025 Earnings Call Transcript
Operator: Good day, ladies and gentlemen, and thank you for standing by. Welcome to ACADIA Pharmaceuticals' Third Quarter 2025 Financial Results Conference Call.
Acadia Pharmaceuticals Inc (ACAD)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Baker Bros. Advisors Julian Baker And Felix Baker | 42,896,690 | $915,415,365 | 6.61% | |
| 2. | Adage Capital Management Phill Gross And Robert Atchinson | 2,484,156 | $53,011,889 | +312% | 0.08% |
| 3. | Palo Alto Investors William Leland Edwards | 2,466,684 | $52,639,037 | -4% | 9.74% |
| 4. | Braidwell LP Alex Karnal | 2,378,655 | $50,760,498 | 1.51% | |
| 5. | Marshall Wace LLP Paul Marshall And Ian Wace | 2,358,881 | $50,338,520 | +20% | 0.05% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $25.65 | 259,109 | $6,646,145.85 | 39,317,673 | 2023-05-24 | Filing | |
| $25.65 | 24,113 | $618,498.45 | 3,610,443 | 2023-05-24 | Filing | |
| $25.51 | 28,878 | $736,787.52 | 39,058,564 | 2023-05-24 | Filing | |
| $25.51 | 2,688 | $68,581.09 | 3,586,330 | 2023-05-24 | Filing | |
| $25.27 | 218,171 | $5,513,682.96 | 39,029,686 | 2023-05-24 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $23.69 | 10,262 | $243,113.96 | 53,338 | 2025-11-18 | Filing | |
| $23.69 | 4,084 | $96,753.64 | 25,058 | 2025-11-18 | Filing | |
| $22.37 | 30,000 | $670,983.00 | 4,041 | 2025-11-10 | Filing | |
| $23.65 | 3,498 | $82,727.70 | 43,447 | 2025-09-15 | Filing | |
| $25.98 | 1,600 | $41,560.48 | 25,382 | 2025-09-02 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 20,268,644 | $432,532,865 | 0.01% | |
| 2. | 15,179,371 | $323,927,778 | 0% | |
| 3. | 7,255,476 | $154,831,858 | 0.01% | |
| 4. | 7,144,524 | $152,464,142 | 1.88% | |
| 5. | 3,132,644 | $66,859,595 | 0% |
News See All
9 Most Profitable Biotech Stocks to Buy
On October 6, StemPoint Capital CIO Michelle Ross appeared on CNBC’s ‘Closing Bell’ to talk about the biotech space.
11 Best Performing Long Term Stocks According to Analysts
Alli McCartney of UBS noted that the market’s behavior after the recent Fed rate cut was unusual. On the day of the cut, major indices closed lower except for the Russell 2000.
ACADIA Pharmaceuticals Inc. (ACAD) Nears Key Phase 3 Readout in Prader-Willi Syndrome
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is a biopharmaceutical company that focuses on therapies for central nervous system disorders and rare diseases.
11 Best Performing Biotech Stocks So Far in 2025
On July 8, Jared Holz of Mizuho spoke on CNBC's "Closing Bell Overtime" about whether the biotech sector is ready for a breakthrough.
ACADIA Pharmaceuticals Inc. (ACAD) Nears Phase 3 Readout in Prader-Willi Syndrome Trial
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is a biopharmaceutical company specializing in therapies for central nervous system disorders and rare diseases.
11 Cheap Biotech Stocks to Buy According to Hedge Funds
Mizuho's Jared Holz appeared on CNBC's "Closing Bell Overtime" on July 8 to talk about whether the biotech industry is prepared for a breakthrough.
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q2 2025 Earnings Call Transcript
Operator: Good day, ladies and gentlemen, and welcome to the ACADIA Pharmaceuticals Conference Call. My name is Gerald, and I'll be your host for today.
Acadia Pharmaceuticals (ACAD) Conducts Inducement Awards to Attract and Retain Top Talent
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is one of the 10 biotech stocks screaming a buy. On June 17, the company moved to attract and retain top talent by granting inducement awards to 41 employees.
10 Biotech Stocks Screaming a Buy
The biotech sector has underperformed the overall market. Those are sentiments echoed by JPMorgan analyst Chris Schott, given the 10% year-to-date loss by the SPDR S&P Biotech ETF.